# CervoMed Inc.: overview

CRVO · Nasdaq · CIK 1053691 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/crvo.md) · [Financials](/companies/crvo/financials.md) · [Filings](/companies/crvo/filings.md) · [Insiders](/companies/crvo/insiders.md)

Latest reported revenue: [$0](/filings/0001437749-26-026592.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001437749-26-026592).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [1,940](/filings/0001437749-25-033879.md) | [2,162 d](/filings/0001437749-26-008259.md) | [1,917](/filings/0001437749-26-017236.md) | [1,758](/filings/0001437749-26-026592.md) | [323](/filings/0001437749-25-033879.md) | [8.7 d](/filings/0001437749-26-008259.md) | [0.0](/filings/0001437749-26-017236.md) | [0.0](/filings/0001437749-26-026592.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(278.2%)](/filings/0001437749-25-033879.md) | [(334.9%) d](/filings/0001437749-26-008259.md) | [(276.6%)](/filings/0001437749-26-017236.md) | [(376.4%)](/filings/0001437749-26-026592.md) | [(2493.8%)](/filings/0001437749-25-033879.md) | [(95479.2%) d](/filings/0001437749-26-008259.md) | not reported | not reported |
| Net margin | % | [(245.1%)](/filings/0001437749-25-033879.md) | [(310.2%) d](/filings/0001437749-26-008259.md) | [(255.2%)](/filings/0001437749-26-017236.md) | [(356.1%)](/filings/0001437749-26-026592.md) | [(2395.3%)](/filings/0001437749-25-033879.md) | [(92680.4%) d](/filings/0001437749-26-008259.md) | not reported | not reported |
| Diluted EPS | $ per share | [(0.55)](/filings/0001437749-24-034344.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | [0.0](/filings/0001437749-24-010064.md) | [7,145](/filings/0001437749-25-007829.md) | [9,738](/filings/0001437749-26-008259.md) | [4,007](/filings/0001437749-26-008259.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(109.3%)](/filings/0001437749-25-007829.md) | [(187.2%)](/filings/0001437749-26-008259.md) | [(706.2%)](/filings/0001437749-26-008259.md) |
| Net margin | % | not reported | not reported | [(30.4%)](/filings/0001437749-25-007829.md) | [(167.3%)](/filings/0001437749-26-008259.md) | [(673.1%)](/filings/0001437749-26-008259.md) |
| Diluted EPS | $ per share | [1946859.00](/filings/0001437749-23-007795.md) | [2038891.00](/filings/0001437749-23-007795.md) | not reported | not reported | not reported |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crvo/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $2.1m | 688,987 |  | New +688,987 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $980.2k | 316,202 |  | Unchanged |
| [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $771.5k | 248,880 |  | New +248,880 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $207.5k | 66,923 |  | Reduced −7,448 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $166.9k | 53,845 |  | Added +2,185 |
| [Byrne Asset Management LLC](/funds/1911322.md) | 2026-06-30 | $158.9k | 51,250 |  | Added +36,550 |
| [CITIZENS FINANCIAL GROUP INC/RI](/funds/759944.md) | 2026-06-30 | $116.2k | 37,477 |  | Unchanged |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $112.1k | 36,151 |  | Unchanged |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $99.9k | 32,231 |  | Added +13,985 |
| [THOMPSON DAVIS & CO., INC.](/funds/1017284.md) | 2026-06-30 | $92.2k | 29,750 |  | Added +19,750 |

## Recent filings

[All 917 filings](/companies/crvo/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:20 ET | [8-K](/filings/0001437749-26-033943.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-033943 |
| 2026-10-14 | 16:05 ET | [8-K](/filings/0001437749-26-032620.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-032620 |
| 2026-10-13 | 08:36 ET | [8-K](/filings/0001437749-26-032502.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032502 |
| 2026-10-09 | 16:06 ET | [8-K](/filings/0001437749-26-032445.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-032445 |
| 2026-09-28 | 17:07 ET | [8-K](/filings/0001437749-26-031389.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031389 |
| 2026-09-10 | 16:07 ET | [8-K](/filings/0001437749-26-030073.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030073 |
| 2026-08-10 | 16:07 ET | [8-K](/filings/0001437749-26-026771.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026771 |
| 2026-08-07 | 16:27 ET | [10-Q](/filings/0001437749-26-026592.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026592 |
| 2026-08-04 | 07:52 ET | [8-K](/filings/0001437749-26-025509.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-025509 |
| 2026-07-14 | 16:21 ET | [8-K](/filings/0001437749-26-023538.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-023538 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-008259.md), filed Mar 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b817ac8c-10a2-4639-84d5-9c3d599aaf0c)

## About the filer

- CIK: 1053691
- Tickers: CRVO
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:21 ET. No prices; not investment advice.